| [1] | Zhang, K., Yang, X., Wang, Y., et al. (2025). Artificial intelligence in drug development. Nat. Med. 31:45−59. DOI:10.1038/s41591-024-03434-4 |
| [2] | The UK Biobank Whole-Genome Sequencing Consortium. (2025). Whole-genome sequencing of 490,640 UK Biobank participants. Nature, 645:692−701. DOI:10.1038/s41586-025-09272-9 |
| [3] | Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596:583−589. DOI:10.1038/s41586-021-03819-2 |
| [4] | Hulcoop, D. G., Trynka, G., & McDonagh, E. M. (2025). Open Targets: 10 years of partnership in target discovery. Nat. Rev. Drug Discov. 24:153−154. DOI:10.1038/d41573-024-00204-2 |
| [5] | Minikel, E. V., Painter, J. L., Dong, C. C., et al. (2024). Refining the impact of genetic evidence on clinical success. Nature, 629:624−629. DOI:10.1038/s41586-024-07316-0 |
| Xie C., Wang X., Dong Y., et al. (2026). Reshaping the drug discovery ecosystem with open science and collaborative innovation. The Innovation Drug Discovery 1:100016. https://doi.org/10.59717/j.xinn-drugdisc.2026.100016 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Transformation from closed to open drug discovery ecosystems